Abstract
Despite intensive treatment, pancreatic adenocarcinoma still has the worst prognosis among all malignancies. Using clinically relevant models, we demonstrated the therapeutic efficacy of adoptively transferred T cells engineered with a carcinoembryonic antigen (CEA)- and ERBB2-specific chimeric antigen receptor against pancreatic carcinoma. Targeting CD24, a putative cancer stem cell antigen expressed by a minority of carcinoma cells, was likewise effective. © 2012 Landes Bioscience.
Author supplied keywords
Cite
CITATION STYLE
Chmielewski, M., Maliar, A., Eshhar, Z., & Abken, H. (2012). CAR’s made it to the pancreas. OncoImmunology. https://doi.org/10.4161/onci.22195
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.